|
|
Current hepatitis B treatment guidelines and future research directions |
Jonathan Skupsky, Ke-Qin Hu() |
Division of Gastroenterology and Hepatology, University of California, Irvine, School of Medicine, Orange, CA 92868, USA |
|
|
Abstract Hepatitis B virus (HBV) infection causes a tremendous clinical burden across the world with more than half a million people dying annually from HBV related disease. Significant advances have been made in HBV treatment in the past decade and several guidelines have been published by professional societies and expert panels. Although these recommendations have been valuable to help optimize HBV treatment, there is discordance in treatment criteria and many patients infected with HBV may fall outside of these recommendations. This paper systematically reviews the natural history of the disease and compares and contrasts the recommendations for initiation of treatment from the various societies. There is also discussion of special groups that require particular consideration and some of the open research questions and future research directions within the field.
|
Keywords
chronic hepatitis B
HBV treatment guidelines
APASL guidelines
EASL guidelines
AASLD guidelines
|
Corresponding Author(s):
Ke-Qin Hu
|
Issue Date: 21 May 2014
|
|
1 |
WHO. “Hepatitis B.” World Health Organization, June 2013
|
2 |
D Ganem, AM Prince. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350(11): 1118− 1129
https://doi.org/10.1056/NEJMra031087
pmid: 15014185
|
3 |
MF Sorrell, EA Belongia, J Costa, IF Gareen, JL Grem, JM Inadomi, ER Kern, JA McHugh, GM Petersen, MF Rein, DB Strader, HT Trotter. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150(2): 104−110
https://doi.org/10.7326/0003-4819-150-2-200901200-00100
pmid: 19124811
|
4 |
ID Gust. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38(Suppl 2): S18−S23
https://doi.org/10.1136/gut.38.Suppl_2.S18
pmid: 8786047
|
5 |
AJ Zuckerman. More than third of world’s population has been infected with hepatitis B virus. BMJ 1999; 318(7192): 1213
https://doi.org/10.1136/bmj.318.7192.1213a
pmid: 10221961
|
6 |
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167−185
pmid: 22436845
|
7 |
A Mason, M Wick, H White, R Perrillo. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993; 18(4): 781−789
https://doi.org/10.1002/hep.1840180406
pmid: 8406351
|
8 |
WM Lee. Hepatitis B virus infection. N Engl J Med 1997; 337(24): 1733−1745
https://doi.org/10.1056/NEJM199712113372406
pmid: 9392700
|
9 |
CM Chu, SJ Hung, J Lin, DI Tai, YF Liaw. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116(12): 829−834
https://doi.org/10.1016/j.amjmed.2003.12.040
pmid: 15178498
|
10 |
MJ Tong, L Hsu, C Hsien, JH Kao, FA Durazo, S Saab, LM Blatt. A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int 2010; 4(2): 516−522
https://doi.org/10.1007/s12072-010-9179-1
pmid: 20827410
|
11 |
CM Chu, YF Liaw. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis 2012; 54(1): 88−90
https://doi.org/10.1093/cid/cir755
pmid: 22052888
|
12 |
A Knöll, M Pietrzyk, M Loss, WA Goetz, W Jilg. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 2005; 79(11): 1631−1633
https://doi.org/10.1097/01.TP.0000163468.80223.74
pmid: 15940056
|
13 |
YF Liaw, JH Kao, T Piratvisuth, HLY Chan, RN Chien, CJ Liu, E Gane, S Locarnini, SG Lim, KH Han, D Amarapurkar, G Cooksley, W Jafri, R Mohamed, JL Hou, WL Chuang, LA Lesmana, JD Sollano, DJ Suh, M Omata. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012. 6(3): 531−561
|
14 |
CJ Chu, EB Keeffe, SH Han, RP Perrillo, AD Min, C Soldevila-Pico, W Carey, RS Brown Jr, VA Luketic, N Terrault, AS Lok. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125(2): 444−451
https://doi.org/10.1016/S0016-5085(03)00895-3
pmid: 12891547
|
15 |
CM Hunt, JM McGill, MI Allen, LD Condreay. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31(5): 1037−1044
https://doi.org/10.1053/he.2000.6709
pmid: 10796877
|
16 |
JH Kao, PJ Chen, MY Lai, DS Chen. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124(2): 327−334
https://doi.org/10.1053/gast.2003.50053
pmid: 12557138
|
17 |
S Sato, K Suzuki, Y Akahane, K Akamatsu, K Akiyama, K Yunomura, F Tsuda, T Tanaka, H Okamoto, Y Miyakawa, M Mayumi. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122(4): 241−248
https://doi.org/10.7326/0003-4819-122-4-199502150-00001
pmid: 7825758
|
18 |
CJ Chen, HI Yang, J Su, CL Jen, SL You, SN Lu, GT Huang, UH Iloeje; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65−73
https://doi.org/10.1001/jama.295.1.65
pmid: 16391218
|
19 |
UH Iloeje, HI Yang, J Su, CL Jen, SL You, CJ Chen; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130(3): 678−686
https://doi.org/10.1053/j.gastro.2005.11.016
pmid: 16530509
|
20 |
P Marcellin, GK Lau, F Bonino, P Farci, S Hadziyannis, R Jin, ZM Lu, T Piratvisuth, G Germanidis, C Yurdaydin, M Diago, S Gurel, MY Lai, P Button, N Pluck; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351(12): 1206−1217
https://doi.org/10.1056/NEJMoa040431
pmid: 15371578
|
21 |
CL Lai, D Shouval, AS Lok, TT Chang, H Cheinquer, Z Goodman, D DeHertogh, R Wilber, RC Zink, A Cross, R Colonno, L Fernandes; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354(10): 1011−1020
https://doi.org/10.1056/NEJMoa051287
pmid: 16525138
|
22 |
CL Lai, E Gane, YF Liaw, CW Hsu, S Thongsawat, Y Wang, Y Chen, EJ Heathcote, J Rasenack, N Bzowej, NV Naoumov, AM Di Bisceglie, S Zeuzem, YM Moon, Z Goodman, G Chao, BF Constance, NA Brown; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357(25): 2576−2588
https://doi.org/10.1056/NEJMoa066422
pmid: 18094378
|
23 |
P Marcellin, EJ Heathcote, M Buti, E Gane, RA de Man, Z Krastev, G Germanidis, SS Lee, R Flisiak, K Kaita, M Manns, I Kotzev, K Tchernev, P Buggisch, F Weilert, OO Kurdas, ML Shiffman, H Trinh, MK Washington, J Sorbel, J Anderson, A Snow-Lampart, E Mondou, J Quinn, F Rousseau. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23): 2442−2455
https://doi.org/10.1056/NEJMoa0802878
pmid: 19052126
|
24 |
TT Chang, YF Liaw, SS Wu, E Schiff, KH Han, CL Lai, R Safadi, SS Lee, W Halota, Z Goodman, YC Chi, H Zhang, R Hindes, U Iloeje, S Beebe, B Kreter. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52(3): 886−893
https://doi.org/10.1002/hep.23785
pmid: 20683932
|
25 |
P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, MK Washington, G Germanidis, JF Flaherty, RA Schall, JD Bornstein, KM Kitrinos, GM Subramanian, JG McHutchison, EJ Heathcote. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468−475
https://doi.org/10.1016/S0140-6736(12)61425-1
pmid: 23234725
|
26 |
MJ Tong, CQ Pan, HW Hann, KV Kowdley, SH Han, AD Min, TS Leduc. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011; 56(11): 3143−3162
https://doi.org/10.1007/s10620-011-1841-5
pmid: 21935699
|
27 |
AS Lok, BJ McMahon. Chronic hepatitis B: update 2009. Hepatology 2009; 50(3): 661−662
https://doi.org/10.1002/hep.23190
pmid: 19714720
|
28 |
EB Keeffe, DT Dieterich, SH Han, IM Jacobson, P Martin, ER Schiff, H Tobias. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6(12): 1315−1341, quiz 1286
https://doi.org/10.1016/j.cgh.2008.08.021
pmid: 18845489
|
29 |
AS Lok, EJ Heathcote, JH Hoofnagle. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001; 120(7): 1828−1853
https://doi.org/10.1053/gast.2001.24839
pmid: 11375963
|
30 |
CJ Chu, M Hussain, AS Lok. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36(6): 1408−1415
https://doi.org/10.1053/jhep.2002.36949
pmid: 12447866
|
31 |
MF Yuen, HJ Yuan, DK Wong, JC Yuen, WM Wong, AO Chan, BC Wong, KC Lai, CL Lai. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54(11): 1610−1614
https://doi.org/10.1136/gut.2005.065136
pmid: 15871997
|
32 |
CJ Liu, BF Chen, PJ Chen, MY Lai, WL Huang, JH Kao, DS Chen. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193(9): 1258−1265
https://doi.org/10.1086/502978
pmid: 16586363
|
33 |
MJ Tong, C Hsien, L Hsu, HE Sun, LM Blatt. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48(4): 1070−1078
https://doi.org/10.1002/hep.22476
pmid: 18688879
|
34 |
CJ Liu, BF Chen, PJ Chen, MY Lai, WL Huang, JH Kao, DS Chen. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006; 194(5): 594−599
https://doi.org/10.1086/505883
pmid: 16897657
|
35 |
YF Liaw. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(Suppl 1): 100−107
https://doi.org/10.1111/j.1478-3231.2008.01941.x
pmid: 19207972
|
36 |
SH Han, FA Durazo, S Saab, MJ Tong. A proposed, evidence-based approach to the treatment of chronic Hepatitis B. J Clin Gastroenterol 2011; 45(3): 259−266
https://doi.org/10.1097/MCG.0b013e3181f312f5
pmid: 20856136
|
37 |
YF Liaw. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009; 51(2): 403−410
https://doi.org/10.1016/j.jhep.2009.04.003
pmid: 19467727
|
38 |
YS Hsu, RN Chien, CT Yeh, IS Sheen, HY Chiou, CM Chu, YF Liaw. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35(6): 1522−1527
https://doi.org/10.1053/jhep.2002.33638
pmid: 12029639
|
39 |
CM Chu, YF Liaw. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133(5): 1458−1465
https://doi.org/10.1053/j.gastro.2007.08.039
pmid: 17935720
|
40 |
YC Chen, CM Chu, YF Liaw. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51(2): 435−444
https://doi.org/10.1002/hep.23348
pmid: 19918971
|
41 |
CM Chu, YF Liaw. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104(7): 1693−1699
https://doi.org/10.1038/ajg.2009.187
pmid: 19455130
|
42 |
JJ Feld, M Ayers, D El-Ashry, T Mazzulli, R Tellier, EJ Heathcote. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007; 46(4): 1057−1070
https://doi.org/10.1002/hep.21811
pmid: 17654702
|
43 |
TC Tseng, CJ Liu, TH Su, CC Wang, CL Chen, PJ Chen, DS Chen, JH Kao. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141(2): 517−525, 525 e1−2
pmid: 21672542
|
44 |
HL Chan, GL Wong, CH Tse, HY Chan, VW Wong. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204(3): 408−414
https://doi.org/10.1093/infdis/jir283
pmid: 21742839
|
45 |
MJ Tong, L Hsu, PW Chang, LM Blatt. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. J Gastroenterol Hepatol 2011; 26(5): 829−835
https://doi.org/10.1111/j.1440-1746.2011.06623.x
pmid: 21214888
|
46 |
WJ Jeng, IS Sheen, YC Chen, CW Hsu, RN Chien, CM Chu, YF Liaw. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58(6): 1888−1896
https://doi.org/10.1002/hep.26549
pmid: 23744454
|
47 |
JG Reijnders, HL Janssen. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty? Hepatology 2013; 58(6): 1885−1887
https://doi.org/10.1002/hep.26708
pmid: 24037945
|
48 |
HL Tillmann, J Hadem, L Leifeld, K Zachou, A Canbay, C Eisenbach, I Graziadei, J Encke, H Schmidt, W Vogel, A Schneider, U Spengler, G Gerken, GN Dalekos, H Wedemeyer, MP Manns. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13(4): 256−263
https://doi.org/10.1111/j.1365-2893.2005.00695.x
pmid: 16611192
|
49 |
WM Lee, RH Squires Jr, SL Nyberg, E Doo, JH Hoofnagle. Acute liver failure: Summary of a workshop. Hepatology 2008; 47(4): 1401−1415
https://doi.org/10.1002/hep.22177
pmid: 18318440
|
50 |
ER Schiff, CL Lai, S Hadziyannis, P Neuhaus, N Terrault, M Colombo, HL Tillmann, D Samuel, S Zeuzem, L Lilly, M Rendina, JP Villeneuve, N Lama, C James, MS Wulfsohn, H Namini, C Westland, S Xiong, GS Choy, S Van Doren, J Fry, CL Brosgart, 0. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38(6): 1419−1427
pmid: 14647053
|
51 |
YF Liaw, JJ Sung, WC Chow, G Farrell, CZ Lee, H Yuen, T Tanwandee, QM Tao, K Shue, ON Keene, JS Dixon, DF Gray, J; Cirrhosis Asian Lamivudine Multicentre Study Group Sabbat. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351(15): 1521−1531
https://doi.org/10.1056/NEJMoa033364
pmid: 15470215
|
52 |
R Perrillo, C Tamburro, F Regenstein, L Balart, H Bodenheimer, M Silva, E Schiff, C Bodicky, B Miller, C Denham, C Brodeur, K Roach, J Albrecht. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109(3): 908−916
https://doi.org/10.1016/0016-5085(95)90401-8
pmid: 7657121
|
53 |
RJ Fontana, HW Hann, RP Perrillo, JM Vierling, T Wright, J Rakela, G Anschuetz, R Davis, SD Gardner, NA Brown. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123(3): 719−727
https://doi.org/10.1053/gast.2002.35352
pmid: 12198698
|
54 |
E Schiff, CL Lai, S Hadziyannis, P Neuhaus, N Terrault, M Colombo, H Tillmann, D Samuel, S Zeuzem, JP Villeneuve, S Arterburn, K Borroto-Esoda, C Brosgart, S Chuck; Adefovir Dipivoxil Study 45 Intrnational Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13(3): 349−360
https://doi.org/10.1002/lt.20981
pmid: 17326221
|
55 |
JH Shim, HC Lee, KM Kim, YS Lim, YH Chung, YS Lee, DJ Suh. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52(2): 176−182
https://doi.org/10.1016/j.jhep.2009.11.007
pmid: 20006394
|
56 |
GV Papatheodoridis, E Cholongitas, AJ Archimandritis, AK Burroughs. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29(9): 1294−1305
https://doi.org/10.1111/j.1478-3231.2009.02085.x
pmid: 19619264
|
57 |
S John, KL Andersson, CN Kotton, M Hertl, JF Markmann, AB Cosimi, RT Chung. Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol 2013; 6(4): 309−319
https://doi.org/10.1177/1756283X13487942
pmid: 23814610
|
58 |
MB Carroll, MA Forgione. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29(9): 1021−1029
https://doi.org/10.1007/s10067-010-1523-2
pmid: 20556450
|
59 |
CM Mastroianni, M Lichtner, R Citton, C Del Borgo, A Rago, H Martini, G Cimino, V Vullo. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881−3887
https://doi.org/10.3748/wjg.v17.i34.3881
pmid: 22025876
|
60 |
C Ferri, M Govoni, L Calabrese. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010; 22(4): 443−450
https://doi.org/10.1097/BOR.0b013e328338f6df
pmid: 20386453
|
61 |
E Iannitto, V Minardi, G Calvaruso, A Mulè, E Ammatuna, R Di Trapani, D Ferraro, V Abbadessa, A Craxí, R Di Stefano. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74(3): 254−258
https://doi.org/10.1111/j.1600-0609.2004.00375.x
pmid: 15693796
|
62 |
SN Pei, CH Chen, CM Lee, MC Wang, MC Ma, TH Hu, CY Kuo. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89(3): 255−262
https://doi.org/10.1007/s00277-009-0806-7
pmid: 19697028
|
63 |
YH Lee, SC Bae, GG Song. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16(5): 527−531
https://doi.org/10.1111/1756-185X.12154
pmid: 24164839
|
64 |
CJ Liu, PJ Chen, DS Chen, JH Kao. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int, 2011.
|
65 |
HR Li, JJ Huang, HQ Guo, X Zhang, Y Xie, HL Zhu, LZ Zhai, XX Pu, Y Huang, CC Guo, TY Lin. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18(12): 877−883
https://doi.org/10.1111/j.1365-2893.2010.01386.x
pmid: 21054683
|
66 |
M Ikeda. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol 2013; 43(1): 8−16
https://doi.org/10.1093/jjco/hys191
pmid: 23183929
|
67 |
M Mandalà, S Fagiuoli, D Francisci, R Bruno, B Merelli, L Pasulo, C Tondini, R Labianca, F Roila. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 2013; 87(1): 12−27
https://doi.org/10.1016/j.critrevonc.2012.12.004
pmid: 23313021
|
68 |
M Long, W Jia, S Li, L Jin, J Wu, N Rao, H Feng, K Chen, H Deng, F Liu, F Su, E Song. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 2011; 127(3): 705−712
https://doi.org/10.1007/s10549-011-1455-9
pmid: 21445574
|
69 |
H Wedemeyer, C Yurdaydìn, GN Dalekos, A Erhardt, Y Çakaloğlu, H Değertekin, S Gürel, S Zeuzem, K Zachou, H Bozkaya, A Koch, T Bock, HP Dienes, MP Manns; HIDIT Study Group.. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364(4): 322−331
https://doi.org/10.1056/NEJMoa0912696
pmid: 21268724
|
70 |
V Soriano, M Puoti, M Bonacini, G Brook, A Cargnel, J Rockstroh, C Thio, Y Benhamou. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19(3): 221−240
pmid: 15718833
|
71 |
S Jamma, G Hussain, DT Lau. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony. Curr Hepat Rep 2010; 9(4): 260−269
https://doi.org/10.1007/s11901-010-0060-4
pmid: 21258658
|
72 |
JK Rockstroh, S Bhagani, Y Benhamou, R Bruno, S Mauss, L Peters, M Puoti, V Soriano, C Tural; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9(2): 82−88
https://doi.org/10.1111/j.1468-1293.2007.00535.x
pmid: 18257771
|
73 |
P Bellecave, J Gouttenoire, M Gajer, V Brass, G Koutsoudakis, HE Blum, R Bartenschlager, M Nassal, D Moradpour. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009; 50(1): 46−55
https://doi.org/10.1002/hep.22951
pmid: 19333911
|
74 |
CJ Chu, SD Lee. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23(4): 512−520
https://doi.org/10.1111/j.1440-1746.2008.05384.x
pmid: 18397482
|
75 |
C.J. Liu,, W.L Chuang, C.M Lee, M.L. Yu, S.N. Lu, S.S. Wu, L.Y. Liao, C.L. Chen, H.T. Kuo, Y.C. Chao, S.Y. Tung, S.S. Yang, J.H. Kao, C.H. Liu, W.W. Su, C.L. Lin, Y.M. Jeng, P.J. Chen, and D.S. Chen, Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology, 2009. 136(2): p. 496−504 e3.
|
76 |
A Potthoff, H Wedemeyer, WO Boecher, T Berg, S Zeuzem, J Arnold, U Spengler, K Gruengreiff, T Kaeser, M Schuchmann, A Bergk, N Forestier, K Deterding, MP Manns, C Trautwein; Hep-Net B/C Co-infection Study Group. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49(5): 688−694
https://doi.org/10.1016/j.jhep.2008.03.028
pmid: 18490077
|
77 |
MM Jonas, JM Block, BA Haber, SJ Karpen, WT London, KF Murray, MR Narkewicz, P Rosenthal, KB Schwarz, BJ McMahon; Hepatitis B Foundation. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010; 52(6): 2192−2205
https://doi.org/10.1002/hep.23934
pmid: 20890947
|
78 |
KF Murray, L Szenborn, J Wysocki, S Rossi, AC Corsa, P Dinh, J McHutchison, PS Pang, LM Luminos, M Pawlowska, J Mizerski. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56(6): 2018−2026
https://doi.org/10.1002/hep.25818
pmid: 22544804
|
79 |
AA Evans, WT London, RG Gish, C Cohen, TM Block. Chronic HBV infection outside treatment guidelines: is treatment needed? Antivir Ther 2013; 18(2): 229−235
https://doi.org/10.3851/IMP2325
pmid: 22914436
|
80 |
YF Liaw. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 53(6): 2121−2129
https://doi.org/10.1002/hep.24364
pmid: 21503943
|
81 |
T Nguyen, AJ Thompson, S Bowden, C Croagh, S Bell, PV Desmond, M Levy, SA Locarnini. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52(4): 508−513
https://doi.org/10.1016/j.jhep.2010.01.007
pmid: 20206400
|
82 |
HL Chan, VW Wong, GL Wong, CH Tse, HY Chan, JJ Sung. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52(4): 1232−1241
https://doi.org/10.1002/hep.23803
pmid: 20648555
|
83 |
J Jaroszewicz, B Calle Serrano, K Wursthorn, K Deterding, J Schlue, R Raupach, R Flisiak, CT Bock, MP Manns, H Wedemeyer, M Cornberg. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52(4): 514−522
https://doi.org/10.1016/j.jhep.2010.01.014
pmid: 20207438
|
84 |
YK Jung, JH Kim, YS Lee, HJ Lee, E Yoon, ES Jung, SK Hong, MK Joo, JE Yeon, JJ Park, JS Kim, YT Bak, KS Byun. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 2010; 44(9): 653−657
pmid: 20216430
|
85 |
MR Brunetto, F Moriconi, F Bonino, GK Lau, P Farci, C Yurdaydin, T Piratvisuth, K Luo, Y Wang, S Hadziyannis, E Wolf, P McCloud, R Batrla, P Marcellin. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49(4): 1141−1150
https://doi.org/10.1002/hep.22760
pmid: 19338056
|
86 |
J Wiegand, H Wedemeyer, A Finger, B Heidrich, J Rosenau, G Michel, CT Bock, MP Manns, HL Tillmann. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 2008; 13(4): 547−554
pmid: 18672533
|
87 |
WK Seto, DK Wong, J Fung, FY Huang, CL Lai, MF Yuen. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58(3): 923−931
https://doi.org/10.1002/hep.26376
pmid: 23468172
|
88 |
Y., Arase,. K. Ikeda, F Suzuki,, Y. Suzuki, S. Saitoh, M. Kobayashi, N. Akuta, T. Someya, T. Hosaka, H. Sezaki, M. Kobayashi, and H. Kumada, Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med, 2006. 119(1): p. 71 e9−16.
|
89 |
EK Manesis, ES Hadziyannis, OP Angelopoulou, SJ Hadziyannis. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12(1): 73−82
pmid: 17503750
|
90 |
MJ Sonneveld, BE Hansen, T Piratvisuth, JD Jia, S Zeuzem, E Gane, YF Liaw, Q Xie, EJ Heathcote, HL Chan, HL Janssen. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58(3): 872−880
https://doi.org/10.1002/hep.26436
pmid: 23553752
|
91 |
TC Tseng, CJ Liu, HC Yang, TH Su, CC Wang, CL Chen, SF Kuo, CH Liu, PJ Chen, DS Chen, JH Kao. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55(1): 68−76
https://doi.org/10.1002/hep.24615
pmid: 21858846
|
92 |
MJ Sonneveld, V Rijckborst, CA Boucher, BE Hansen, HL Janssen. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52(4): 1251−1257
https://doi.org/10.1002/hep.23844
pmid: 20830787
|
93 |
S.J. Hadziyannis,, V. Sevastianos, I. Rapti, D. Vassilopoulos, and E. Hadziyannis, Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology, 2012. 143(3): p. 629−36 e1.
|
94 |
LC da Silva, ML Nova, SK Ono-Nita, JR Pinho, R Sitnik, VA Santos, FJ Carrilho. Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2009; 51(5): 261−268
https://doi.org/10.1590/S0036-46652009000500005
pmid: 19893978
|
95 |
RA Heijtink, J Kruining, P Honkoop, MC Kuhns, WC Hop, AD Osterhaus, SW Schalm. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J Med Virol 1997; 53(3): 282−287
https://doi.org/10.1002/(SICI)1096-9071(199711)53:3<282::AID-JMV18>3.0.CO;2-J
pmid: 9365897
|
96 |
JM Lee, SH Ahn, HS Kim, H Park, HY Chang, Y Kim, SG Hwang, KS Rim, CY Chon, KH Han, JY Park. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53(5): 1486−1493
https://doi.org/10.1002/hep.24221
pmid: 21520167
|
97 |
GV Matthews, RJ Ali, A Avihingsanon, J Amin, R Hammond, S Bowden, SR Lewin, J Sasadeusz, M Littlejohn, SL Locarnini, K Ruxrungtham, GJ Dore. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS ONE 2013; 8(4): e61297
https://doi.org/10.1371/journal.pone.0061297
pmid: 23593455
|
98 |
R Perrillo, L Mimms, K Schechtman, D Robbins, C Campbell. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993; 18(6): 1306−1312
https://doi.org/10.1002/hep.1840180604
pmid: 8244253
|
99 |
AJ Thompson, T Nguyen, D Iser, A Ayres, K Jackson, M Littlejohn, J Slavin, S Bowden, EJ Gane, W Abbott, GK Lau, SR Lewin, K Visvanathan, PV Desmond, SA Locarnini. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51(6): 1933−1944
https://doi.org/10.1002/hep.23571
pmid: 20512987
|
100 |
X Zhang, SM Lin, F Ye, TY Chen, M Liu, YR Chen, SQ Zheng, YR Zhao, SL Zhang. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients. J Viral Hepat 2011; 18(7): e184−e190
https://doi.org/10.1111/j.1365-2893.2010.01423.x
pmid: 21692931
|
101 |
D Cai, C Mills, W Yu, R Yan, CE Aldrich, JR Saputelli, WS Mason, X Xu, JT Guo, TM Block, A Cuconati, H Guo. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56(8): 4277−4288
https://doi.org/10.1128/AAC.00473-12
pmid: 22644022
|
102 |
GBL Palumbo, N Pediconi, M Levrero. Targeting the cccDNA by epigenetic drugs inhibits HBV transcription and replication. in The Liver Meeting 2013. 2013. Washington, DC: AASLD
|
103 |
TM Block, R Gish, H Guo, A Mehta, A Cuconati, W Thomas London, JT Guo. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res 2013; 98(1): 27−34
https://doi.org/10.1016/j.antiviral.2013.01.006
pmid: 23391846
|
104 |
T Volz, L Allweiss, M Ben MBarek, M Warlich, AW Lohse, JM Pollok, A Alexandrov, S Urban, J Petersen, M Lütgehetmann, M Dandri. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58(5): 861−867
https://doi.org/10.1016/j.jhep.2012.12.008
pmid: 23246506
|
105 |
ML Michel, Q Deng, M Mancini-Bourgine. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54(6): 1286−1296
https://doi.org/10.1016/j.jhep.2010.12.031
pmid: 21238516
|
106 |
S Pol, B Nalpas, F Driss, ML Michel, P Tiollais, J Denis, C Brécho; Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34(6): 917−921
https://doi.org/10.1016/S0168-8278(01)00028-9
pmid: 11451177
|
107 |
M Mancini-Bourgine, H Fontaine, D Scott-Algara, S Pol, C Bréchot, ML Michel. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40(4): 874−882
https://doi.org/10.1002/hep.20408
pmid: 15382173
|
108 |
SM Akbar, S Furukawa, N Horiike, M Abe, Y Hiasa, M Onji. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat 2011; 18(6): 408−414
https://doi.org/10.1111/j.1365-2893.2010.01320.x
pmid: 20487261
|
109 |
B Engels, W Uckert. Redirecting T lymphocyte specificity by T cell receptor gene transfer—a new era for immunotherapy. Mol Aspects Med 2007; 28(1): 115−142
https://doi.org/10.1016/j.mam.2006.12.006
pmid: 17307249
|
110 |
RE Lanford, B Guerra, D Chavez, L Giavedoni, VL Hodara, KM Brasky, A Fosdick, CR Frey, J Zheng, G Wolfgang, RL Halcomb, DB Tumas. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144(7): 1508−1517, 1517 e1−10
pmid: 23415804
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|